On September 11, 2012, we issued a press release announcing the pre-planned interim efficacy and safety recommendation by the independent Data and Safety Monitoring Board of our pivotal Phase 3 VALOR trial of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

(d) Exhibits.

Exhibit No.                                  Description

99.1              Press Release, dated September 11, 2012, entitled "Sunesis
                  Pharmaceuticals to Implement One-Time Sample Size Increase to
                  Phase 3 VALOR Trial in AML"